Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Non-Inferiority 'Mistake' Hits E-Therapeutics' Depression Ambition

This article was originally published in Scrip

Executive Summary

"Our mistake was to structure the trial as a non-inferiority to amitriptyline study," e-Therapeutics CEO Malcolm Young told Scrip. "We should have called it a 'dose-ranging' study – which is what it was." The company saw its share price plummet on Feb. 15 following top-line results from its Phase IIb trial of ETS6103 (a controlled-release formulation of the analgesic tramadol) in major depressive disorder, which failed to meet its efficacy endpoint of establishing non-inferiority when compared to amitriptyline.


Related Content

Can Barlow Flip E-Therapeutics From A Miss To A Hit?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts